Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) compared with systemic therapy alon...

Descripción completa

Detalles Bibliográficos
Autores principales: Tibdewal, Anil, Agarwal, JaiPrakash, Mummudi, Naveen, Noronha, Vanita, Prabhash, Kumar, Patil, Vijay, Purandare, Nilendu, Janu, Amit, Kaushal, Rajiv, Kannan, Sadhna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887350/
https://www.ncbi.nlm.nih.gov/pubmed/33589450
http://dx.doi.org/10.1136/bmjopen-2020-041345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887350/
https://www.ncbi.nlm.nih.gov/pubmed/33589450
http://dx.doi.org/10.1136/bmjopen-2020-041345

Ejemplares similares